论文部分内容阅读
目的:研究替米沙坦对醋酸去氧皮质酮(DOCA)高血压大鼠肾脏保护作用和足细胞Podocalyxin蛋白表达的影响。方法:18只雄性Wistar大鼠随机分为对照组(A组)、高血压组(B组)和替米沙坦治疗组(C组)。单肾切除后皮下注射DOCA(5 mg/只,2次/周)和饮用盐水(1%Nacl+0.2%KCl)建立高血压模型。C组用替米沙坦[5mg/(kg.d)]灌胃。测定第4、8周尿蛋白。8周后处死动物,测血肌酐(SCr)、血钠、血钾,取肾组织PAS染色观察病理变化,免疫组化法检测肾脏podocalyxin表达变化。结果:B组4周始血压和尿蛋白较A组逐渐升高(P<0.05)。B组肾小球硬化指数和间质纤维化指数均明显高于A组(P<0.05),podocalyxin蛋白表达较A组降低。C组血压、尿蛋白和病理损伤较B组减轻,podocalyxin表达显著高于B组(P<0.05)。结论:替米沙坦通过上调足细胞podocalyxin表达,减轻DOCA高血压大鼠肾损伤。
AIM: To investigate the effects of telmisartan on renal protection and Podocalyxin protein expression in podocytes of DOCA hypertensive rats. Methods: Eighteen male Wistar rats were randomly divided into control group (A group), hypertension group (B group) and telmisartan treatment group (C group). Hypertensive models were established by subcutaneous injection of DOCA (5 mg twice daily) and saline (1% Nacl + 0.2% KCl) following a single nephrectomy. C group with telmisartan [5mg / (kg.d)] intragastric administration. The 4th and 8th week urine protein was measured. After 8 weeks, the animals were sacrificed, serum creatinine (SCr), serum sodium and potassium were measured. PAS staining was used to observe the pathological changes. The expression of podocalyxin in kidney was detected by immunohistochemistry. Results: The blood pressure and urinary protein in group B at 4 weeks were higher than those in group A (P <0.05). B group glomerular sclerosis index and interstitial fibrosis index were significantly higher than the A group (P <0.05), podocalyxin protein expression was lower than the A group. Blood pressure, urinary protein and pathological changes in group C were relieved compared with those in group B, and the expression of podocalyxin was significantly higher than that in group B (P <0.05). Conclusion: Telmisartan can reduce podocalyxin expression in podocytes and alleviate renal damage in DOCA hypertensive rats.